Federated Hermes, Inc. Arcus Biosciences, Inc. Transaction History

Federated Hermes, Inc.

$43 Billion
Q4 2024

A detailed history of Federated Hermes, Inc. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 2,893 shares of RCUS stock, worth $27,714. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,893

Previous 3,178 8.97%

Holding current value

$27,714

Previous $48,000 10.42%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$14.28 - $18.44 $4,069 - $5,255	-285 Reduced 8.97%	2,893 $43,000
Q3 2024 Nov 13, 2024	BUY	$13.69 - $18.01 $43,506 - $57,235	3,178 New	3,178 $48,000
Q3 2023 Nov 13, 2023	SELL	$17.62 - $23.54 $674,370 - $900,946	-38,273 Reduced 97.22%	1,095 $19,000
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $592,507 - $769,177	34,915 Added 784.08%	39,368 $799,000
Q1 2023 May 08, 2023	BUY	$15.96 - $23.15 $35,159 - $50,999	2,203 Added 97.91%	4,453 $81,000
Q4 2022 Feb 13, 2023	BUY	$19.7 - $35.71 $2,482 - $4,499	126 Added 5.93%	2,250 $46,000
Q3 2022 Nov 14, 2022	BUY	$23.23 - $30.07 $49,340 - $63,868	2,124 New	2,124 $56,000
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $61,011 - $133,601	-3,541 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$28.92 - $41.83 $293,162 - $424,030	-10,137 Reduced 74.11%	3,541 $111,000
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $257,472 - $397,696	8,205 Added 149.92%	13,678 $553,000
Q3 2021 Nov 15, 2021	BUY	$26.93 - $37.68 $140,493 - $196,576	5,217 Added 2037.89%	5,473 $191,000
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $4.3 Million - $6.77 Million	-189,137 Reduced 99.86%	256 $7,000
Q1 2021 May 13, 2021	BUY	$26.16 - $41.39 $4.94 Million - $7.82 Million	188,881 Added 36890.82%	189,393 $5.32 Million
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $1.99 Million - $3.78 Million	-116,773 Reduced 99.56%	512 $13,000
Q3 2020 Nov 12, 2020	BUY	$17.14 - $25.47 $1.12 Million - $1.66 Million	65,060 Added 124.58%	117,285 $2.01 Million
Q2 2020 Aug 13, 2020	SELL	$13.97 - $36.56 $631,192 - $1.65 Million	-45,182 Reduced 46.38%	52,225 $1.29 Million
Q1 2020 May 13, 2020	BUY	$8.78 - $19.28 $801,693 - $1.76 Million	91,309 Added 1497.36%	97,407 $1.35 Million
Q4 2019 Feb 14, 2020	SELL	$7.33 - $10.79 $2,983 - $4,391	-407 Reduced 6.26%	6,098 $62,000
Q3 2019 Nov 14, 2019	SELL	$6.44 - $10.18 $528 - $834	-82 Reduced 1.24%	6,505 $59,000
Q2 2019 Aug 14, 2019	BUY	$7.29 - $13.38 $6,123 - $11,239	840 Added 14.62%	6,587 $53,000
Q1 2019 May 10, 2019	BUY	$8.95 - $12.49 $18,240 - $25,454	2,038 Added 54.95%	5,747 $72,000
Q4 2018 Feb 13, 2019	SELL	$9.74 - $14.5 $2,259 - $3,364	-232 Reduced 5.89%	3,709 $39,000
Q3 2018 Nov 13, 2018	BUY	$10.88 - $14.95 $42,878 - $58,917	3,941 New	3,941 $55,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.2M

Call Options Held

288K

Put Options Held

138K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $691M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Arcus Biosciences, Inc. Transaction History